

Preclinical Assessment of ^{212}Pb - Radio-DARPin Therapeutic (RDT) Targeting DLL3 in SCLC



Amelie Croset, PhD

Senior Director - Head of Preclinical Platforms at Molecular Partners

EANM - 22 October 2024

Disclosures

- The presented research was funded by Molecular Partners and Orano Med
- All authors are employees of Molecular Partners or Orano Med
- Amelie Croset owns stocks in Molecular Partners

MP0712, the first ^{212}Pb -DLL3 targeted radiotherapy

Combining distinctive DARPin features with the power of ^{212}Pb for efficacious cancer therapy



HALF-LIFE
EXTENSION

**Tunable
albumin binding**

MP0712 properties

- Specific binding with **high affinity**
 - Affinity to hDLL3: 0.2 nM by SPR
 - Human cell binding: ~ 2 nM on NCI-H82 ± HSA
- **Good developability**

SCLC as indication

- **Aggressive cancer** with high **unmet medical need**
 - 2L: mPFS ~3m; 5y OS ~3%^{1,2}
- **DLL3 is expressed in >85% of patients**³

DLL3 – a promising target

- **Homogeneous tumor expression**, but low expression level in patients
- No expression in healthy tissues
- **New treatments with room for improvement:** Tarlatamab (AMGEN) for 2L+; ORR ~40%

Molecular Partners

- **New class of therapeutics:** Designed Ankyrin Repeat Proteins (DARPins)
- **DARPins close gap** between small molecules and antibodies
- **7 clinical-stage compounds**, > 2500 patients treated

^{212}Pb for Targeted Alpha Therapy

- **Strong cytotoxicity** (dsDNA breaks)
- **Single alpha decay** (limited free daughters)
 - Limited irradiation of healthy tissues
- Relatively **short half-life** (10.6 h)
 - **Fast energy deposition** (efficacy)
 - **Easier waste management**

Collaboration with Orano Med

- The **leader for ^{212}Pb** & a committed partner
- **Reliable & scalable ^{212}Pb production**
- **Independent production** capacities (substantial inventory of purified ^{232}Th)

ASCO: Ph2 clinical data


^{212}Pb -DOTAMTATE (AlphaMedix™)

*showed an **ORR of 55.6%***⁴


MP0712 showed favorable biodistribution and tumor specificity

DLL3 expression & distribution by IHC


NCI-H82 tumors




hDLL3-MC38 tumors



Human SCLC tumors




R2G2 mice xenografted s.c. with NCI-H82



T:K at 4h = 0.6 / at 24h = 1.2




R2G2 mice xenografted i.v. with NCI-H82



T:K at 4h = 2.1 / at 24h = 2.6




ATH nude mice double xenografted s.c. with hDLL3-MC38 + WT-MC38




T:K at 4h = 2.3 / at 24h = 3

- MP0712 reached T:K ratios > 2 in mouse model matching clinically relevant DLL3 expression levels
- Selective uptake in DLL3-expressing tumors confirmed high target specificity of MP0712


MP0712 showed a favorable safety profile



- Complete recovery of body weight loss after 10 days
- Complete recovery of hematologic profile after 28 days
- MP0712 treatment up to 30 μ Ci well tolerated



MP0712 showed good efficacy & tumor stabilization




Median survival

Buffer	MP0712 1x10 μ Ci	MP0712 4x10 μ Ci	Rova 1x10 μ Ci	Rova 4x10 μ Ci
4.7 wks	7.9 wks	15.7 wks	7.9 wks	8.9 wks




R2G2 mice xenografted s.c. with
NCI-H82

Tumor growth curve for each animal



- **MP0712 induced tumor stabilization in NCI-H82 tumor model**

MP0712 showed good efficacy & tumor stabilization




Median survival

Buffer	MP0712 1x10 μ Ci	MP0712 4x10 μ Ci	Rova 1x10 μ Ci	Rova 4x10 μ Ci
4.7 wks	7.9 wks	15.7 wks	7.9 wks	8.9 wks



R2G2 mice xenografted s.c. with
NCI-H82

Effect of MP0712 cycles in tumor vs necrotic area




- Significant effect of MP0712 treatment on tumor vs necrotic tissue after cycles 3 and 4.

- **MP0712 induced tumor stabilization in NCI-H82 tumor model**
- **A significant induction of necrotic vs tumor tissue was observed post MP0712 treatment**

Summary

- ✓ **MP0712, the first ^{212}Pb -DLL3 Targeted Radio-DARPin Therapy**
 - High tumor uptake
 - Reached T:K > 2 in mouse models expressing DLL3
 - Showed a favorable safety profile *in vivo* up to 30 μCi
 - Induced good efficacy & tumor stabilization
- ✓ **IND-enabling package** about to be completed
- ✓ **Initial FIH clinical data** expected in 2025!



TARGET	RESEARCH	DEV.	RIGHTS
DLL3	MP0712		MOLECULAR partners
Target 2			oranomed
Target A			MOLECULAR partners
Target B			
Target X			NOVARTIS
Target Y			
Several targets in evaluation			

Outlook

- **Advance MP0712 and additional pipeline candidates**
- **Continue to evolve our RDT platform**
- **Progress collaboration projects with Orano Med**

Acknowledgments

The joint team at Orano Med & Molecular Partners

Contributing authors of this presentation

Amelie Croset¹, Amal Saidi², Francesca Malvezzi¹, Tania Stallons², Madlaina Mettier¹, Amy Wong², Jitka Rantanen¹, Federico Rojas Quijano², Stephan Wullschleger¹, Yvonne Kaufmann¹, Tamara Lekishvili¹, Stefanie Riesenberger¹, Jacqueline Blunski¹, Liridon Abduli¹, Christian Reichen¹, Christian Lizak¹, Aaron Schatzmann², Anne Goubier¹, Julien Torgue², Daniel Steiner¹



Molecular Partners Team

¹ Molecular Partners AG, Zurich-Schlieren, Switzerland

² Orano Med LLC, Plano, TX, USA

Thank you for your interest!



Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners' product candidates, the selection and development of future programs, and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2024 and its expectation of its current cash runway. These statements may be identified by words such as "guidance", "believe", "expect", "may", "plan", "potential", "will", "would" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may impact Molecular Partners' financial and business projections and guidance and may cause Molecular Partners' actual results and outcomes to materially differ from its guidance; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with Securities and Exchange Commission (SEC) on March 14, 2024 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.